摘要
目的观察抗病毒药物拉米夫定对慢性重型乙型病毒性肝炎患者生存率的影响。方法采用配对的回顾性队列研究方法,对1999年10月至2003年12月住院的慢性重型乙型病毒性肝炎患者,根据年龄、性别和病程3个变量对应用拉米夫定和未用拉米夫定治疗的患者进行匹配,比例为1∶1。配对结果为拉米夫定治疗组103例,未用拉米夫定组103例。对研究对象进行随访并比较两组中位生存时间及生存率的差别。结果拉米夫定治疗组中位生存时间为85d,3年生存率为42.7%;未用拉米夫定组中位生存时间为35d,3年生存率为23.4%,两组之间生存率有明显差异(P<0.01)。结论应用拉米夫定治疗可提高慢性重型乙型病毒性肝炎患者的生存率。
Objective To investigate the survival rate of patients with chronic severe hepatitis B (CSH) after lamivudine treatment. Method A matched retrospective cohort study using data on patients derived from a prospectively collected chronic severe hepatitis B database was conducted. The database included patients who received or did not receive lamivudine treatment from October, 1999 to December, 2003. The match was con- ducted according with 3 variables : sex, age and duration of disease. The match ratio was 1 : 1. Cases were patients who received lamivudine treatment (n = 103 ). Controls were patients who did not receive lamivudine treatment (n = 103). All the patients were followed up and their median survival time and survival rate were compared and evaluated. Results The median survival time in lamivudine treatment group and control group were 85 and 35 d respectively. The survival rate for 3 years in treatment group and control group were 42.7% and 23.4% respectively. There was significance difference in survival rate between the 2 groups ( P 〈 0.01 ). Conclusion Lamivudine may improve survival of patients with chronic severe hepatitis B.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2008年第1期75-77,共3页
Journal of Third Military Medical University